Table 1. Significant results from the KORA F4 analysis for rs4329.
| metabolic trait | n (non-users) | beta (non-users) | p-value (non-users) | p-gain (non-users) | n (users) | beta (users) | p-value (users) | n AA | beta AA | p-value AA | n AG | beta AG | p-value AG | n GG | beta GG | p-value GG |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| aspartylphenylalanine | 1013 | -0.306 | 6.04 x10-11 | 265 | -0.053 | 0.556 | 284 | -0.762 | 1.61x10-15 | 521 | -0.497 | 1.92 x10-09 | 208 | -0.120 | 0.235 | |
| aspartylphenylalanine / HWESASXX | 981 | -0.356 | 5.33 x10-14 | 1133.15 | 261 | -0.106 | 0.248 | 274 | -1.000 | 1.84 x10-25 | 506 | -0.702 | 3.29 x10-17 | 201 | -0.252 | 0.014 |
| aspartylphenylalanine / X11805 | 1009 | -0.503 | 9.16 x10-28 | 6.60x1016 | 259 | -0.216 | 0.019 | 282 | -1.491 | 7.25 x10-52 | 520 | -1.050 | 4.57 x10-42 | 207 | -0.638 | 2.81 x10-11 |
| aspartylphenylalanine / phenylalanylleucine (X14450) | 872 | -0.407 | 4.71 x10-16 | 128329.95 | 222 | -0.128 | 0.197 | 245 | -1.198 | 2.40 x10-31 | 456 | -0.830 | 1.28 x10-21 | 171 | -0.437 | 1.81 x10-05 |
| X14086 | 1024 | -0.347 | 6.39 x10-14 | 259 | 0.027 | 0.767 | 286 | -1.074 | 2.26 x10-28 | 526 | -0.828 | 2.03 x10-24 | 212 | -0.494 | 1.16 x10-06 | |
| leucylalanine (X14189) pos. mode | 1022 | -0.434 | 2.65 x10-21 | 254 | -0.001 | 0.987 | 287 | -1.250 | 1.29 x10-38 | 522 | -1.012 | 1.80 x10-37 | 213 | -0.466 | 3.35 x10-07 | |
| α-glutamyltyrosine (X14205) | 934 | -0.336 | 3.02 x10-12 | 138 | -0.279 | 0.023 | 266 | -1.337 | 1.26 x10-29 | 477 | -1.105 | 2.51 x10-27 | 191 | -0.771 | 1.43 x10-10 | |
| phenylalanylserine (X14208) | 1025 | -0.373 | 5.95 x10-16 | 179 | -0.008 | 0.945 | 286 | -1.507 | 2.03 x10-41 | 528 | -1.269 | 7.91 x10-44 | 211 | -0.901 | 1.18 x10-15 | |
| leucylalanine (X14304) neg. mode | 916 | -0.396 | 2.26 x10-15 | 169 | 0.040 | 0.723 | 269 | -1.253 | 1.88 x10-30 | 484 | -0.899 | 1.89 x10-22 | 163 | -0.532 | 2.14 x10-06 |
Columns 2–8 give the results of the linear regression tests between metabolites (metabolite ratios, respectively) and the ACE-SNP rs4329. The linear regression tests were separately applied for ACE inhibitor users (users) and individuals who take no antihypertensives (non-users). Results with a p-value smaller than 1.4x10-8 (0.05/(517*(517/2) metabolite ratios + 517 metabolites)/25 SNPs) and with a p-gain greater than 517 (for ratios) were considered as significant.
Columns 9–17 show the results of the linear regression tests comparing the metabolite levels of each genotype group of the non-users (AA: major homozygotes, AG: heterozygotes, GG minor homozygotes) with those of all ACE inhibitor users. n gives the number of non-users in each genotype group.